Sandoz Says Amgen’s At-Risk Aflibercept Launch ‘Doesn’t Change Our Thinking’
FDA Approval For Sandoz’s Enzeevu Biosimilar Is In Hand, But Launch Date Unclear
Sandoz has indicated that Amgen’s recently-announced at-risk US launch of a rival to Eylea doesn’t change its thinking around launch timing for its own FDA-approved aflibercept biosimilar.
